The Federal Trade Commission is urging the Supreme Court to prevent brand-name drugmakers from paying rival generic-drug makers to delay the availability of cheaper generic drugs. The justices will listen to arguments today in a case that will affect the health of patients as well as drug prices. "A lot of us take prescription drugs, and price is a significant factor," Rutgers-Camden law professor Michael Carrier said. "The price difference between a brand-name drug and a generic can be astronomical." Drugmakers say the settlements can bring generics to consumers years earlier than the drugs would arrive if the cases were litigated.
Published in Brief: